Alethio Therapeutics, an Oxford spinout developing a mutation-agnostic antibody for essential thrombocythemia, raised $90 million in an oversubscribed Series A. The financing funds ATX-011 through Phase I/IIa studies, aiming to reach Phase III readiness after early safety and first-in-patient data. ATX-011 is designed as a monoclonal antibody against the platelet receptor G6B, with a proposed mechanism of boosting platelet clearance and potentially affecting myeloproliferative neoplasm stem-cell biology. Investors including Sofinnova Partners and RA Capital co-led the round, with additional support from Cancer Research Horizons and the University of Oxford. The round underscores sustained appetite for targeted, biomarker-defined rare hematology assets that can address thrombosis risk where existing therapies remain blunt or slow.